Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

200883 citationsJournal Article

Authors

Alessandra Fusco

Ginette Gunz · Institut de Neurophysiopathologie

P Jaquet · Institut de Neurophysiopathologie

Henry Dufour · Assistance Publique Hôpitaux de Marseille

Anne Laure Germanetti

Michael D. Culler · Ipsen (United States)

Anne Barlier · Centre de Recherche en Neurobiologie - Neurophysiologie de Marseille

Alexandru Saveanu

Abstract

Although the SSTRs are expressed in prolactinomas, the somatostatinergic ligands analyzed do not appear to be highly effective in suppressing PRL. D2DR remains the primary target for effective treatment of prolactinomas.

Topics & Keywords

Pituitary Gland Disorders and Treatments Neuroendocrine Tumor Research Advances Growth Hormone and Insulin-like Growth Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Endocrinology

Volume 158, Issue 5, pp. 595-603

DOI: 10.1530/eje-07-0806

Field-Weighted Citation Impact: 4.33